Certified Global Research Member
Key Questions Answered
- Global Market Outlook
- In-depth analysis of global and regional trends
- Analyze and identify the major players in the market, their market share, key developments, etc.
- To understand the capability of the major players based on products offered, financials, and strategies.
- Identify disrupting products, companies, and trends.
- To identify opportunities in the market.
- Analyze the key challenges in the market.
- Analyze the regional penetration of players, products, and services in the market.
- Comparison of major players’ financial performance.
- Evaluate strategies adopted by major players.
- Recommendations
Why Choose Market Research Future?
- Vigorous research methodologies for specific market.
- Knowledge partners across the globe
- Large network of partner consultants.
- Ever-increasing/ Escalating data base with quarterly monitoring of various markets
- Trusted by fortune 500 companies/startups/ universities/organizations
- Large database of 5000+ markets reports.
- Effective and prompt pre- and post-sales support.
Theranostics is affected by growing cancer and cardiovascular disease rates. Theranostics customizes treatment strategies for chronic and complex disorders by combining targeted therapy and diagnostics.
Continuous molecular imaging technology developments boost theranostics market. Advanced imaging methods like SPECT and PET increase diagnostic accuracy and enable more targeted therapy.
The trend to precision oncology and individualized care drives theranostics adoption. Theranostic approaches let physicians customize medicines for each patient, improving effectiveness and reducing side effects.
Partnerships between drug and diagnostic firms influence theranostics. Partnerships simplify integrated medicinal and diagnostic solutions, improving patient care and market growth.
Government funding and research in theranostics affect market dynamics. Government assistance encourages innovation and theranostic technology incorporation into therapeutic settings, driving market growth.
Nanotechnology in theranostic applications affects market growth. Nanoparticles and nanomaterials improve theranostic therapy by tailoring drug distribution and imaging contrast.
The aging population means more complex medical concerns that require specific treatment approaches, which boosts theranostics sales. Theranostics are expected to rise as the population ages.
Cancer strongly influences theranostics, which focuses on biomarkers. Cancer research is increasing the use of theranostics for diagnosis and treatment.
Theranostics are affected by healthcare infrastructure expansion, especially in emerging nations. Accessible healthcare facilities with cutting-edge diagnostic and treatment equipment enable theranostic patient care.
Patient education and awareness drive market growth. As patients learn about theranostics' benefits, personalized diagnostic and treatment solutions may become more popular.
Regulations severely effect theranostics sales. Integrating diagnostic and therapeutic items requires regulatory approval to access the market. Regulatory modifications and faster approvals affect treatment introduction rates.
Theranostics Market Highlights:
Theranostics Market Scenario
The Theranostics Market is expected to reach USD 1,731.78 Million by 2030 at 9.80% CAGR during the forecast period 2022-2030. Theranostics is referred to as the combination of therapeutics, nanoscience, and diagnostics that provides a transition from conventional medicine to a contemporary personalized and precision medicine approach. Theranostics is also called as theragnostics or companion diagnostics (CDx), or pharmacodiagnostics or personalized medical care, or personalized therapy, or personalized medicine technology.
It is a new field of medicine which combines specific targeted therapy based on specific targeted diagnostic tests. Factors responsible for the growth of the market are globally increasing the development of novel companion diagnostic tests, mounting adoption of companion diagnostic tests by end users, increasing collaborations and partnerships by prominent market participants to develop innovative companion diagnostics, and rising burden of chronic diseases. For instance, according to the World Health Organization (WHO), in 2001, chronic diseases contributed approximately 60% of the 56.5 million total reported deaths in the world and around 46% of the global burden of disease; these diseases are forecasted to account for about three-quarters of all deaths worldwide by the end of 2020. On the contrary, the lack of properly defined regulations for theranostics tests and inadequate reimbursement facilities in most of the economies are anticipated to limit the theranostics market size during the forecast period from 2019 to 2025.
Theranostics Market Segmentation
The theranostics market has been segmented into the therapeutic area, technology, end user, and region.
By therapeutic area, the market has been segmented into oncology, cardiovascular diseases, neurological disorders, immunological disorders, and others. The oncology segment is further categorized into breast cancer, colorectal cancer, lung cancer, cervical cancer, and others. The oncology segment dominated the market in 2018 and expected to retain its dominance over the forecast period due to increasing adoption of theranostics in cancer disease to eliminate multi-step procedures, reduce delays in treatment and improves patient care.
On the basis of technology, the market has been divided into polymerase chain reaction (PCR), immunohistochemistry (IHC), in situ hybridization (ISH), sequencing, and others.
Based on end user, the market has been classified into hospitals and clinics, diagnostic laboratories, and others.
The theranostics market has been segmented on the basis of region into the Americas, Europe, Asia-Pacific, and the Middle East & Africa. The market in the Americas has further been segmented into North America and Latin America, with the North American market divided into the US and Canada.
The European theranostics market has been segmented into Western Europe and Eastern Europe. Western Europe, market, has further been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe.
The theranostics market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. The market in the Middle East & Africa has been segmented into the Middle East and Africa.
Theranostics Market Key Players
- Thermo Fisher Scientific Inc.
- Beckman Coulter, Inc.
- Hoffmann-La Roche Ltd
- Focus Diagnostics
- Illumina, Inc.
- Agilent Technologies, Inc.
- QIAGEN
- Abbott Laboratories
- Myriad Genetics, Inc.
- Foundation Medicine, Inc.
- AmeriPath, Inc.
Regional Market Summary
Theranostics Market Share (%), by Region, 2018 
Source: White Papers, Company Presentations, Annual Reports, and MRFR Analysis
Geographically, the Americas held substantial market share in 2018 attributed to the presence of key market players, rising prevalence of chronic diseases, strong research and development activities, and increasing adoption of companion diagnostics in the US and Canada. The presence of market players, namely, Thermo Fisher Scientific Inc., Beckman Coulter, Inc., Abbott Laboratories, and Agilent Technologies, Inc. facilitates early market initiation of products and prompt products supply to the customers, thereby supporting to its dominance.
Europe would be the second largest value contributor in the global market due to proliferating pharmaceutical and medical device companies, increasing partnerships and collaborations between life science companies and medical diagnostics companies, and growing focus of major market players on the expansion of product portfolio. For instance, in June 2018, Laboratory Corporation of America Holdings and Unilabs (a Swiss provider of clinical laboratory testing and medical diagnostic imaging services) strategically collaborated to provide expanded global development and delivery of companion diagnostics.
Increasing awareness regarding companion diagnostics, rising collaborations between medical diagnostic companies, growing elderly population coupled with surging prevalence of serious health illnesses are expected to contribute to the lucrative market growth of Asia-Pacific. In August 2018, QIAGEN N.V. collaborated with SRL, Inc., a Japan-based clinical lab testing company, to introduce new companion diagnostics simultaneous with new drug approvals.
The theranostics market in the Middle East & Africa would witness the modest market growth rate from 2018 to 2025. The Middle East would spearhead the market attributed to growth in the healthcare sector along with developing healthcare infrastructure in the Gulf Cooperation Council (GCC) region.
by Therapeutic Area
- Oncology
- Breast Cancer
- Colorectal Cancer
- Lung Cancer
- Cervical Cancer
- Others
- Cardiovascular Diseases
- Neurological Disorders
- Immunological Disorders
- Others
by Technology
- Polymerase Chain Reaction (PCR)
- Immunohistochemistry (IHC)
- In Situ Hybridization (ISH)
- Sequencing
- Others
by End User
- Hospitals and Clinics
- Diagnostic Laboratories
- Others
by Region
- Americas
- North America
- US
- Canada
- Latin America
- Europe
- Western Europe
- Germany
- France
- Italy
- Spain
- UK
- Rest of Western Europe
- Eastern Europe
- Asia-Pacific
- Japan
- China
- India
- Australia
- South Korea
- Rest of Asia-Pacific
- Middle East & Africa
- Middle East
- Africa
Intended Audience
- Medical diagnostic manufacturers
- Medical diagnostic suppliers
- Venture capitalists
- Medical devices companies
- Research and academic institutes
- Healthcare facilities
- Association and government bodies
- Market research and consulting service providers
- Corporate entities
Leading companies partner with us for data-driven Insights
Kindly complete the form below to receive a free sample of this Report
Tailored for You
- Dedicated Research on any specifics segment or region.
- Focused Research on specific players in the market.
- Custom Report based only on your requirements.
- Flexibility to add or subtract any chapter in the study.
- Historic data from 2014 and forecasts outlook till 2040.
- Flexibility of providing data/insights in formats (PDF, PPT, Excel).
- Provide cross segmentation in applicable scenario/markets.
